However, CCL5 is a double-edged sword in cancer, because it also promotes antitumor immunity by recruiting anti-tumor T cells and dendritic cells to the TME, and therefore enhances the immunotherapy response in different tumor types [21,22,23,24,25]. The gene discussed is CCL5; the disease is cancer.